Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The XV19 TCR did not bind CD1d–α-GalCer but showed approximately equivalent affinity for the two CD1d-sulfatide antigens C24:1 sulfatide and C24:0 sulfatide. This indicated that the different reactivity of the XV19 NKT cell hybridoma to different forms of sulfatide antigens was more attributable to loading and antigen-presentation mechanisms, analogous to the reactivity of type I NKT cells to lipid-based antigens with modifications in their acyl chains. The micromolar affinity of the XV19 TCR–CD1d-sulfatide interaction was in contrast to the nanomolar affinity of type I NKT cell TCRs for CD1d–α-GalCer and was more similar to the affinity of autoreactive type I NKT cell TCRs for β-linked self antigens such as β-GalCer and iGb3 and was also in the range typically associated with the recognition of complexes of peptide and major histocompatibility complex class I by TCRs.
There are currently no customer reviews or questions for Mouse anti-C48H93NO11S T cell receptor (XV19), pCDTCR1 (TCR-YC0241). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
